Fintel reports that on March 13, 2025, Chardan Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Neutral to Buy. As of March 4, 2025, the average one-year price target for CervoMed is ...

Fintel reports that on March 13, 2025, Jones Trading upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to Buy. As of March 4, 2025, the average one-year price target for CervoMed is $20.66 ...

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies ...

Participants on New Capsules showed a lower increase in dementia severity than those on Old Capsules. Chardan upgraded CervoMed to Buy, citing compelling 16-week extension data. Get a Year of Fast, ...

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how CervoMed Inc. (NASDAQ:CRVO) compares to the other top short squeeze stocks that ...

CervoMed (NASDAQ:CRVO – Get Free Report) had its target price lifted by equities research analysts at Canaccord Genuity Group from $12.00 to $21.00 in a report issued on Tuesday,Benzinga reports. The ...